RNS Number: 1367 J Indivior PLC 08 April 2020. Slough, UK, and Richmond, VA- 8 April 2020- Indivior PLC today provides the following business update.. The Company does not expect to be in a position to provide revised guidance until the duration and extent of the market disruptions from the COVID-19 pandemic are known. As of March 31, 2020, Indivior had gross cash of...

RNS Number: 6078 H Indivior PLC 25 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 6056 H Indivior PLC 25 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 2592 H Indivior PLC 23 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 1737 H Indivior PLC 23 March 2020. One-Year Outcomes of Real-World RECOVER™ Study Published in Journal of Addiction Medicine. Slough, UK and Richmond, VA, March 23, 2020- Indivior PLC today announced the publication of one-year outcomes from a 24- month real-world observational study, RECOVER™..

RNS Number: 0464 H Indivior PLC 20 March 2020 TR-1: S tandard form for notification of major holdings. i Please note that national forms may vary due to specific national legislation as for instance the applicable thresholds or information regarding capital holdings.. Indicate in the relevant section whether the issuer is a non UK issuer..

RNS Number: 8484 G Indivior PLC 19 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 1168 G Indivior PLC 13 March 2020 INDIVIOR PLC. The Company announces that on March 13, 2020, Conditional Awards over Ordinary Shares of $0.10 each were granted to the Executive Directors set out below under the Indivior Deferred Bonus Plan 2018. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the...

RNS Number: 1170 G Indivior PLC 13 March 2020 March 13, 2020. Indivior PLC Annual Financial Report. The Company has today posted or made available to shareholders the following documents:.

RNS Number: 8255 F Indivior PLC 11 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 5832 F Indivior PLC 10 March 2020 INDIVIOR PLC. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM. The Company announces that on March 9, 2020 it granted Conditional Awards over Ordinary Shares of US $0.10 each in the Company under the Indivior...

RNS Number: 4192 F Indivior PLC 09 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 8872 E Indivior PLC 03 March 2020 INDIVIOR PLC. The Company announces that it received notification on March 2, 2020 that Graham Hetherington, a Non-Executive Director of the Company, acquired 30,000 shares at a price of £0.4446 per share. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United...

RNS Number: 6661 E Indivior PLC 02 March 2020 INDIVIOR PLC- TOTAL VOTING RIGHTS AND CAPITAL. In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6. 1, the Company hereby notifies the market that as at March 1, 2020 the Company's issued share capital consisted of 732,408,332 O rdinary Shares of US $0.10 each. RNS is approved by the Financial...

RNS Number: 0891 E Indivior PLC 25 February 2020 INDIVIOR PLC. The Company announces that it received notification on February 24, 2020 that Graham Hetherington, a Non-Executive Director of the Company, acquired 20,000 shares at a price of £0.3754 per share. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the...

RNS Number: 0447 E Indivior PLC 25 February 2020 INDIVIOR PLC. The Company announces that it was notified on February 24, 2020 of the following changes to the interests of persons discharging managerial responsibilities in the Ordinary Shares of $0.10 each in the Company. RNS is approved by the Financial Conduct Authority to act as a Primary Information...

RNS Number: 9837 C Indivior PLC 14 February 2020 TR-1: S tandard form for notification of major holdings. i Please note that national forms may vary due to specific national legislation as for instance the applicable thresholds or information regarding capital holdings.. Indicate in the relevant section whether the issuer is a non UK issuer..

RNS Number: 9085 C Indivior PLC 13 February 2020 Indivior PLC- Board Committee Changes. Slough, UK and Richmond, VA, February 13, 2020- Indivior PLC announces that Daniel Tass é will step down as Chair of the Audit Committee and Graham Hetherington will take on the role of Chair of that Committee. RNS is approved by the Financial Conduct Authority to act as a Primary...

RNS Number: 8384 C Indivior PLC 13 February 2020 pdf. FY 2019 Adjusted Financial Results In-Line with Guidance. Supported by our enhanced compliance capabilities to meet the growing number of buprenorphine medication-assisted treatment patients and prescribers, we expect these...